The CAPTAIN trial compared the MRI-Guided TULSA Procedure™ to robotic radical prostatectomy for localized prostate cancer.

Mar 27, 2026, 7:45 AM ETProfound Medical Corp. (PROF), PRN:CA The TULSA Procedure, performed using the TULSA-PRO ® system, represents a major advancement in prostate care, and is used by physicians to ...

– First multicenter, randomized controlled trial directly comparing a new technology to robotic RP for men with localized prostate cancer to successfully recruit to target enrollment – – TULSA ...

Primary endpoint analysis at 1 year showed better maintenance of erectile function and pad-free continence with TULSA than with robotic radical prostatectomy. Peri-procedural metrics favored TULSA, ...

Profound Medical Corp. (NASDAQ:PROF) is one of the best Canadian stocks with huge upside potential. On June 10, Profound Medical announced the successful completion of the first commercial benign ...

The Society of Interventional Radiology (SIR) announced that the CAPTAIN randomized clinical trial found that men with ...

Transurethral ultrasound ablation (TULSA) procedures are performed using the TULSA-PRO system when treating people who have prostate disease, including an enlarged prostate and prostate cancer. There ...

TORONTO, April 01, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets AI-powered, ...